Please use this identifier to cite or link to this item:
https://dora.health.qld.gov.au/qldresearchjspui/handle/1/6178| Title: | Secondary Analysis of the MM21 Trial: Response Adaptive Salvage Treatment with Daratumumab-Lenalidomide-Dexamethasone (DRd) for Newly Diagnosed Transplant Eligible Multiple Myeloma Patients Failing Front-Line Bortezomib-Based Induction Therapy | Authors: | Sueh-li Lim John Reynolds Hang Quach Anna Hutchinson Ian H Kerridge Jane Estell Wallington-Gates, Craig Anna Kalff Flora Yuen Andrew Spencer |
Issue Date: | 2022 | Source: | Blood, 2022 | Journal Title: | Blood | DOI: | 10.1182/blood-2022-170697 | metadata.dc.rights.holder: | Craig Wallington-Gates | Type: | Article |
| Appears in Sites: | Sunshine Coast HHS Publications |
Show full item record
Items in DORA are protected by copyright, with all rights reserved, unless otherwise indicated.